Xilio Therapeutics Inc. (XLO)
Xilio Therapeutics Statistics
Share Statistics
Xilio Therapeutics has 51.78M shares outstanding. The number of shares has increased by 40.26% in one year.
| 51.78M |
| 40.26% |
| 17.78% |
| 40.74% |
| n/a |
| 174,713 |
| 14.01% |
Short Selling Information
The latest short interest is 1.22M, so 2.35% of the outstanding shares have been sold short.
| 1.22M |
| 2.35% |
| 3.44% |
| 1 |
Valuation Ratios
The PE ratio is -0.88 and the forward PE ratio is -0.83. Xilio Therapeutics's PEG ratio is 0.01.
| -0.88 |
| -0.83 |
| 8.06 |
| 3.5 |
| 2.9 |
| -2.78 |
| 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Xilio Therapeutics.
| n/a |
| n/a |
| n/a |
| n/a |
Financial Position
The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.46.
| 2.21 |
| 2.21 |
| 0.46 |
| -0.14 |
| -0.44 |
| 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| n/a |
| n/a |
| n/a |
| $99,125 |
| $-910,015.62 |
| 64 |
| 0.09 |
| n/a |
Taxes
| n/a |
| 0% |
Stock Price Statistics
The stock price has increased by -34.31% in the last 52 weeks. The beta is 0.02, so Xilio Therapeutics's price volatility has been higher than the market average.
| 0.02 |
| -34.31% |
| 0.78 |
| 0.89 |
| 42.39 |
| 1,246,853 |
Income Statement
In the last 12 months, Xilio Therapeutics had revenue of 6.34M and earned -58.24M in profits. Earnings per share was -1.09.
| 6.34M |
| 4.7M |
| -60.58M |
| -58.24M |
| -56.5M |
| -59.65M |
| -1.09 |
Balance Sheet
The company has 55.29M in cash and 8.14M in debt, giving a net cash position of 47.15M.
| 55.29M |
| 8.14M |
| 47.15M |
| -383.75M |
| 103.72M |
| 45.56M |
Cash Flow
In the last 12 months, operating cash flow was -18.38M and capital expenditures -36K, giving a free cash flow of -18.41M.
| -18.38M |
| -36K |
| -18.41M |
| -0.34 |
Margins
Gross margin is 74.09%, with operating and profit margins of -954.95% and -918.05%.
| 74.09% |
| -954.95% |
| -918.05% |
| -918.05% |
| -890.56% |
| -954.95% |
| -290.26% |
Dividends & Yields
XLO does not appear to pay any dividends at this time.
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Analyst Forecast
The average price target for XLO is $4, which is 497% higher than the current price. The consensus rating is "Buy".
| $4 |
| 497% |
| Buy |
| 1 |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| n/a |
| n/a |
| n/a |
| n/a |
Scores
| -6.23 |
| 4 |